Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer

NCT01703065 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01703065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01703065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
June 18, 2013
Completion date
September 18, 2015
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate, castration-resistant prostate cancer, recurrent prostate cancer, stage iii prostate cancer, stage iv prostate cancer